ACHN—Perhaps it's on the pricing of the offering, I'm not sure. Surprised to see the stock up so much on no concrete news.
Everyone knew the company needed cash, and they got cash at a discount of only 2% to Tuesday’s closing price with no warrants. That’s a positive development for a clinical-stage biotech company.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”